The X-Linked Lymphoproliferative Syndrome Gene Product SH2D1A Associates with p62dok(Dok1) and Activates NF-κ B

The X-linked lymphoproliferative syndrome (XLP) is a genetic disorder in which affected males have a morbid or fatal response to Epstein-Barr virus infection. The XLP deficiency has been mapped to a gene encoding a 128-residue protein, SH2D1A, which is comprised principally of a Src homology 2 (SH2)...

Full description

Saved in:
Bibliographic Details
Published inProceedings of the National Academy of Sciences - PNAS Vol. 97; no. 13; pp. 7470 - 7475
Main Authors Sylla, Bakary S., Murphy, Kerry, Cahir-McFarland, Ellen, Lane, William S., Mosialos, George, Kieff, Elliott
Format Journal Article
LanguageEnglish
Published United States National Academy of Sciences of the United States of America 20.06.2000
National Acad Sciences
The National Academy of Sciences
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The X-linked lymphoproliferative syndrome (XLP) is a genetic disorder in which affected males have a morbid or fatal response to Epstein-Barr virus infection. The XLP deficiency has been mapped to a gene encoding a 128-residue protein, SH2D1A, which is comprised principally of a Src homology 2 (SH2) domain. We now report that SH2D1A associates with Dok1, a protein that interacts with Ras-GAP, Csk, and Nck. An SH2D1A SH2 domain mutant that has been identified in XLP does not associate with Dok1, in accord with the hypothesis that this interaction is linked to XLP. The association of SH2D1A with Dok1 also depends on phosphorylation of Dok1 Y449in the sequence ALYSQVQK. Further, overexpression of SH2D1A is found to activate NF-κ B in 293T cells. NF-κ B activation by SH2D1A does not depend on the wild-type SH2 domain and is inhibited by a dominant-negative Iκ B kinase β . Thus, SH2D1A can affect multiple intracellular signaling pathways that are potentially important in the normal effective host response to Epstein-Barr virus infection.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Present address: Biomedical Sciences Research Center “Al. Fleming,” 14–16 Al. Fleming Street, Vari 16672, Greece.
To whom reprint requests should be addressed. E-mail: ekieff@rics.bwh.harvard.edu.
Contributed by Elliott Kieff
Present address: International Agency for Research on Cancer, F-69372 Lyon, France.
ISSN:0027-8424
1091-6490
DOI:10.1073/pnas.130193097